A b s t r a c t
Multiparameter flow cytometry, a powerful tool for nonHodgkin lymphoma (NHL) diagnosis, is capable of detecting very small clonal B-cell populations. However, on occasion, small clonal B-cell populations are discovered incidentally in patients in whom there is no strong clinical suspicion of lymphoma. Several groups have described CD5-"benign monoclonal B lymphocytosis" or "B lymphocytosis of undetermined significance" as a virtually nonprogressing lymphocytosis with a stable clinical course. [1] [2] [3] [4] In addition, it recently has been reported that minute clonal populations with immunophenotypic characteristics of chronic lymphocytic leukemia (CLL) may be observed in a small minority of healthy adults. 5, 6 However, to date, a systematic assessment of the immunophenotypic spectrum and the clinical significance of incidentally detected clonal B-cell populations is largely lacking.
We reviewed our institutional experience with incidental small B-cell clones in blood and bone marrow samples assessed with broad 3-or 4-color flow cytometric panels. We reviewed follow-up information to determine the proportion of patients who were found to have or in whom overt NHL eventually developed. The immunophenotypic and clinical features in patients with and without overt NHL were compared.
Materials and Methods

Patients
The University of Texas Southwestern Medical Center (Dallas) Flow Cytometry Laboratory database was searched for the period April 1994 to December 2002 for blood or bone marrow specimens satisfying the following criteria: (1) no history or significant clinical suspicion of B-cell non-Hodgkin lymphoma (no clinically evident lymphadenopathy or organomegaly) and (2) the presence of clonal B-lymphocyte populations constituting fewer than 5% of total events. We found 93 cases in which incidental clonal B-cell populations were detected, which represented 0.809% of 11,500 peripheral blood and bone marrow samples assessed during the specified period. We excluded 24 cases because of lack of clinical follow-up, leaving 69 cases in the final cohort (31 men and 38 women). Clinical data were obtained through chart review and clinician contact. Patients were classified as having overt lymphoma if compelling clinical, radiologic, or pathologic evidence of lymphoma was obtained on further evaluation. This study was reviewed and approved by the University of Texas Southwestern Institutional Review Board.
Flow Cytometry
Specimen Processing
Peripheral blood or bone marrow specimens were processed using RBC lysis by a standard ammonium chloride lysing solution at a ratio of 1 part sample to 5 parts lysing solution and incubated for 10 minutes. The samples were washed twice with phosphate-buffered saline, 0.0455% sodium azide, and 0.1% bovine serum albumin solution (PAB) and resuspended in 5% newborn calf serum in RPMI 1640 culture medium. Cell counts were performed, and 500,000 cells were washed with PAB and stained with a 3-or 4-color combination of antibodies. The amount of antibody added was determined by the manufacturer's recommendations, with titration used when needed. Specimens were incubated at 2°C to 8°C in the dark for 20 minutes. They then were washed with PAB and resuspended in 1% paraformaldehyde in phosphatebuffered saline. At least 30,000 events were acquired routinely using a FACSCalibur (4-color) or FACSort (3-color) flow cytometer (Becton Dickinson [BD] Immunocytometry Systems, San Jose, CA) with CellQuest software (BD). Data analysis was performed using Paint-a-Gate software (BD).
Antibodies
Antibodies to the following lymphoid antigens conjugated to fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein, and allophycocyanin were used (from BD unless otherwise specified): CD2 (S5.2), CD3 (SK7), CD4 (SK3), CD5 (L17F12), CD7 (4H9), CD8 (SK1), CD10 (W8E7), CD11c (S-HCL-3), CD19 (SJ25C1), CD20 (L27), CD22 (S-HCL-1), CD22 (4KB128; DAKO, Carpinteria, CA), CD23 (B6), CD38 (HB7), CD45 (2D1), CD45RO (UCHL-1), CD56 (MY31), FMC7, monoclonal κ (TB28-2), monoclonal λ (I-155-2), polyclonal κ (IgG goat), and polyclonal λ (goat IgG; Coulter Immunotech, Miami, FL). In addition, CD25 (2A3) and CD103 (2G5.1; Coulter Immunotech) were used to characterize clonal B cells in cases in which hairy cell leukemia (HCL) was suspected. A portion of every specimen was stained with isotype-matched fluorescent control monoclonal antibodies. The antibody panel used differed based on the type of specimen, the indication for study, and the date of accessioning. Because of this fact, CD38 was not assessed specifically on the clonal populations in all cases.
Analysis
Distinct cell populations (clusters) were identified based on any combination of forward and orthogonal light scatter properties and fluorescence intensity with various antibody combinations. An antigen was considered positive in a population when at least 10% of the cluster of interest exceeded a 2% isotypic control threshold. Percentages of various cell types were determined based on total events. Monoclonality was demonstrated by immunoglobulin light chain restriction in the populations of interest.
Immunophenotypic Classification
Cases with a CD5+/CD10-immunophenotype were subdivided into 3 categories: (1) CD5+/CD23+/FMC7+, consistent with CLL; (2) CD5+/CD23-/FMC7+, resembling mantle cell lymphoma; and (3) CD5+ indeterminate (CD5+-I), defined as lack of expression or coexpression of CD23 and FMC7. Cases with CD10 expression were defined as such regardless of other antigen expression. An HCL immunophenotype was defined as CD5-, CD10-, CD11cbright+, CD22bright+, CD25+, and CD103+. The remaining cases with a CD5-/CD10-immunophenotype were otherwise unspecified.
Statistical Analysis
The means of continuous variables were compared with independent sample t tests. Categorical variables (sex, immunophenotype group) were analyzed with 2-tailed χ 2 tests or Fisher exact tests. P values of less than .05 were considered statistically significant.
Results
Patient Characteristics
There were 31 men and 38 women in the final cohort, aged 20 to 89 years (median, 71 years). Samples included 7 peripheral blood and 62 bone marrow specimens. The most common indications for flow cytometric study were various cytopenias (45 patients). Other indications are listed in ❚Table 1❚.
Follow-up Information
In 49 cases (71%), there was no clinical evidence of NHL with follow-up periods of 0.5 to 72 months (median, 16 months). In 20 cases (29%), there was clinical or pathologic confirmation of NHL at 0 to 40 months from the flow cytometric study (median, 0 months). In 14 cases, there was definite biopsy confirmation of lymphoma: 9 with bone marrow biopsies showing low-grade lymphoma infiltration; 1 with subsequent development of diffuse large B-cell lymphoma; 1 with morphologic evidence of HCL in peripheral blood and subsequent development of diffuse large B-cell lymphoma; 1 with a resected spleen showing low-grade lymphoma; 1 with evidence of multiorgan involvement by splenic marginal zone lymphoma at autopsy; and 1 with atypical lymphocytes in lymph node and marked splenomegaly. Of the remaining 6 cases without biopsy confirmation of lymphoma, Waldenström macroglobulinemia developed in 1, and the other 5 showed overt clinical evidence of lymphoma, consisting of multifocal lymphadenopathy. Two of these patients died of what was considered clinically to be end-stage low-grade lymphoma.
❚Table 2❚ details concurrent clinical conditions in all patients in whom overt lymphoma did not develop during the follow-up period. The most common conditions were myelodysplastic syndromes, postchemotherapy status for acute leukemia or solid organ neoplasms, and infections, mainly viral, including cytomegalovirus, hepatitis C infection, and HIV. Other concurrent conditions included idiopathic thrombocytopenic purpura and chronic diseases such as hypertension and chronic heart failure.
Comparison of Clinical and Hematologic Data in Patients With and Without Overt Lymphoma
There were no significant differences in age, sex, hemoglobin concentration, WBC counts, and platelet counts between patients with and without overt lymphoma ❚Table 3❚. The mean absolute lymphocyte count in patients without lymphoma ( total events represented by the clonal B-cell populations in these bone marrow samples were 0.40%, 1.3%, and 0.50%. In these 3 cases T cells constituted 8.2%, 1.4%, and 1.7% of events and normal polyclonal B cells, 0.43%, 0%, and 0.27%. One of these patients had cytogenetically confirmed chronic myelogenous leukemia. The other 2 patients had neutrophilia but no other clinical or morphologic evidence of a myeloproliferative disorder. None of these patients had morphologic evidence of lymphoma on marrow examination. Three patients had clonal B-cell populations with an HCL immunophenotype. Notably, none of these had splenomegaly. Two patients had no evidence of overt lymphoma 58 and 49 months after initial study. The first had monocytopenia but no neutropenia, and the peripheral blood smear contained rare cells suggestive of hairy cells. The other had normal monocyte and neutrophil counts, and no hairy cells were observed in a bone marrow aspirate smear. The third patient had monocytopenia, neutropenia, and circulating hairy cells on a blood smear, and thus, the disease was classified as overt HCL. This patient developed a large B-cell lymphoma 6 months from the initial evaluation.
Immunophenotypic Features
We identified 70 distinct clonal B-cell populations in 69 patients, ranging from 0.05% to 4.5% (median, 1.28%; mean, 1.53%) of total events. One patient had 2 distinct clones (0.6% CD5+/CD23+/FMC7-and 3.4% CD5-/CD10-). The mean percentage of clonal B cells in patients with overt lymphoma (mean, 1.73%; median, 1.50%; range, 0.25%-4.0%) was not significantly higher than in those without lymphoma (mean, 1.45%; median, 1.10%; range, 0.05%-4.5%; P = .18).
Immunophenotypic features of the 70 clonal populations are summarized in ❚Table 4❚. There were no significant differences in the distribution of immunophenotypic categories between patients with and without overt lymphoma. Overall, the most common immunophenotype was CD5-/CD10-, followed by CD5+/CD23+/FMC7-, CD5+-I, CD10+, and HCL. The least common type was CD5+/CD23-/FMC7+; neither of the 2 patients with this immunophenotype had overt lymphoma. ❚Image 1❚, ❚Image 2❚, and ❚Image 3❚ show examples of clonal B-cell populations with CD5+/CD23+/FMC7-, CD5+/CD23-/FMC7+, and CD5-/CD10-immunophenotypes. Among CD5+/CD23+/FMC7-cases with evaluable CD38, 2 (40%) of 5 with overt lymphoma and 2 (17%) of 12 without expressed CD38 (P = .54).
Follow-up Studies
Follow-up flow cytometric studies to assess the evolution of clones were available for 11 of 49 patients without overt lymphoma ❚Table 5❚. Seven patients had persistence of clonal populations with the same immunophenotype from 1 week to 1 year after the initial study. The percentage of the populations at follow-up analysis (mean, 1.68%; median, 0.9%; range, 0.23%-6.0%) was not different from that at first analysis (mean, 1.57%; median, 1.5%; range, 0.4%-3.3%; P = .44). Four patients had a disappearance of their clones, 2 at first follow-up and 2 at second follow-up. 
Discussion
We retrospectively analyzed our experience with small, incidentally discovered clonal B-cell populations. We found such populations in approximately 0.8% of peripheral blood and bone marrow samples. One goal of our study was to determine the clinical significance of incidentally encountered clonal B-cell populations. Based on our data, in at least 29% of cases these are manifestations of early or clinically occult NHL. However, longer follow-up periods clearly are necessary to assess the true risk of progression to overt NHL in these patients. It is possible that there will continue to be a low rate of conversion to overt NHL over many years in these patients, analogous to monoclonal gammopathies of undetermined significance. 7 It seems, though, that in the relatively short term, many of these clonal populations carry little clinical significance. Also, based on our data, there is no way to immunophenotypically distinguish clonal populations that represent overt lymphoma from those that are bound to remain subclinical for prolonged periods.
The literature provides precedent for clinically benign clonal B-cell populations in blood or marrow samples. For example, it has been recently reported that minute clonal Bcell populations with immunophenotypic characteristics of CLL are present in a minority (3.5%-5.5%) of healthy adults or elderly persons with normal blood counts. 5, 6 These occur 100 times more frequently than overt clinical CLL, so it is assumed that only a very small proportion of such cases progress to clinical disease. Clonal B-cell populations with a non-CLL phenotype also are reported to occur in 1% to 1.4% of healthy individuals. 5, 6 Along similar lines, several groups have described nonprogressive lymphocytosis with a stable clinical course for many years with designations such as "benign monoclonal lymphocytosis" 1 and "monoclonal B-cell lymphocytosis of undetermined significance (MLUS)." 8 Such cases differ from those we describe, in that they manifest as absolute lymphocytosis. Although 3 of 69 patients in our series had slight absolute lymphocytosis, the lymphocytosis occurred in a background of neutrophilia. One of these patients had concurrent chronic myelogenous leukemia. It is possible that the slight lymphocytosis in the other 2 cases represented transient stress lymphocytosis, 9 although available clinical details are sketchy in these cases. The very small size of the clonal populations might support this interpretation. The detection rate of small clonal populations was lower than that seen in other studies. 5, 6 However, our study differed in several significant respects from those of Rawstron et al 5 and Ghia et al. 6 First, our samples were primarily bone marrow specimens, rather than peripheral blood samples. Second, our patients had a wide array of medical conditions and were studied for a variety of clinical indications. Third, and probably most important, the previous studies were prospective surveys using optimized analyses to detect minute CLL populations. Our study was a retrospective review of clonal populations detected during routine clinical analysis by a number of individuals using standard operating procedures. Thus, our results are a representation of clonal populations likely to be encountered in routine clinical practice rather than a true prevalence in our patient population.
In our study, the most common immunophenotype was CD5-/CD10-, followed by a CLL-like immunophenotype. In contrast, Rawstron et al 5 and Ghia et al 6 reported that a CLLlike immunophenotype was several times more common than a CD5-/CD10-immunophenotype. This discrepancy might be explained by the gating strategies used in those studies, which were designed specifically to identify CLL populations (eg, based on dim CD20 and/or expression of CD5). Detection of CD5-/CD10-populations, a more technically difficult issue, seemed to rely in these studies primarily on skews in the κ/λ ratios. This is a rather insensitive approach in the presence of background polyclonal cells. In our laboratory, rather than using a fixed gating strategy, we use a flexible approach that is driven by the specific characteristics of the populations in any given sample. Thus, we define discrete B-cell populations on any combination of forward and orthogonal light scatter properties and fluorescence parameters. Light chain restriction and other immunophenotypic features then are assessed directly within these populations. This flexible approach enhances the detection of small clones in a polyclonal background, provided a population deviates in one or more ways from normal B cells.
In addition to CD5-/CD10-and CLL-like immunophenotypes, we also had small numbers of cases with very indolent course in CLL. [10] [11] [12] [13] [14] [15] In accordance with these data, Rawstron et al 5 reported that the small CLL populations in healthy patients had these favorable characteristics. In our study, 17% of the CLL populations in patients who lacked overt lymphoma expressed CD38 in greater than 30% of the clonal cells, compared with the 26% to 47% of patients with clinical CLL described in the literature. [11] [12] [13] [14] [15] There were too few patients in our study with overt lymphoma and a CLL immunophenotype for a meaningful comparison. The true biologic characteristics of the incidental clonal B-cell populations that do not seem to represent overt lymphoma remain unknown. It is conceivable that in at least some circumstances they represent an exaggerated oligoclonal proliferation in response to antigenic stimulation. Such a phenomenon has been documented in tissue sites in reactive states. [16] [17] [18] In 4 cases, the clones disappeared after varying periods, suggesting that they represented transient clonal Bcell proliferations. However, the persistence of these populations in the majority of the patients with follow-up studies would argue against this hypothesis, although in some the follow-up period was relatively short. In addition, many of these immunophenotypes resembling mantle cell lymphoma and follicular lymphoma, as well as CD5+ cases with otherwise indeterminate immunophenotypes. To our knowledge, populations with these immunophenotypes have not been reported in the context of incidental clones in blood and marrow. Interestingly, both patients with an immunophenotype resembling mantle cell lymphoma lacked signs of overt lymphoma, although follow-up periods were only 2.5 and 4 months. Because information regarding the presence or absence of a t(11;14) was not available in these patients, the relationship of these clones to mantle cell lymphoma is unclear. Overall, there was no difference in the distribution of immunophenotypes between patients with and without overt lymphoma. While cases with a CD5-/CD10-and an indeterminate CD5+ immunophenotype seemed to be underrepresented and overrepresented, respectively, in the group without evidence of overt lymphoma, neither of these differences achieved statistical significance (P = .19 and P = .60, respectively).
Multiple groups have shown that mutated immunoglobulin heavy chain genes and lack of CD38 expression predict a populations demonstrate aberrant B-cell antigen expression relative to normal B-cell populations (data not shown), suggesting that these actually are neoplastic. It is possible that at least some of these populations represent premalignant neoplastic proliferations that have not yet accrued sufficient genetic events to manifest an "invasive" phenotype. Studies of these populations for acquired genetic abnormalities might shed light on these issues. We detected incidental clonal B-cell populations in approximately 0.8% of blood and bone marrow samples in our laboratory. Based on relatively limited follow-up, at least 29% of these populations represent manifestations of clinically occult NHL or eventually will progress to overt NHL. We found a broad range of immunophenotypes, most commonly CD5-/CD10-and CLL-like, but also profiles that have not been reported in this context. While longer follow-up clearly is required to assess the risk of progression to overt lymphoma in these patients, our results and those of others suggest that in some patients, incidentally encountered B-cell clones might not be clinically important. 
